Showing results (331-340 of 351) with videos related to

Sort By:
Pageof 36
Arthritis and Rheumatism|January 7, 1998
A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosisL Guillevin, J F Cordier, F Lhote, et al.
Annals of the Rheumatic Diseases|June 1, 2010
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian populationP Dieudé, M Guedj, J Wipff, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 22, 2019
Early-onset granulomatous arthritis, uveitis and skin rash: characterization of skin involvement in Blau syndromeJ Poline, O Fogel, C Pajot, et al.
Clinical Immunology (Orlando, Fla.)|August 21, 2018
Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patientsA C Desbois, L Biard, O Addimanda, et al.
Annals of the Rheumatic Diseases|August 24, 2011
Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypesJasmin B Kuemmerle-Deschner, E Hachulla, R Cartwright, et al.
Annales De Medecine Interne|January 1, 1996
Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patientsP Cohen, Q T Nguyen, P Dény, et al.
Arthritis and Rheumatism|October 31, 2009
BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4P Dieudé, J Wipff, M Guedj, et al.
The British Journal of Dermatology|October 9, 2012
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trialS Prey, K Ezzedine, A Doussau, et al.
Arthritis and Rheumatism|December 14, 2004
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonistJ H Korn, M Mayes, M Matucci Cerinic, et al.
Annals of the Rheumatic Diseases|December 15, 2010
NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesisP Dieudé, M Guedj, J Wipff, et al.
Pageof 36